Other medications of use in ADHD

Author/s
David M. Foreman
Citation
Issue 2 Spring 2012
CEPiP.2012.1.46-50
Abstract

Perhaps as many as 20% of individuals with ADHD will not respond adequately to the three medications recommended in the current NICE guideline. This paper considers treatments that are not recommended in the guideline but appear to be useful in the treatment of ADHD. The effect size and common language effect size (CLES) are definedandare quotedwhere datais available,as a guide to choosing effective alternatives. The alternative medications considered include clonidine, atypical antipsychotics, antidepressants, modafinil, and amantadine.

Cite as: Cutting Edge Psychiatry in Practice 2012, 2(1):46-50; https://doi.org/10.65031/yant5100

References

  1. Green H, McGinnity A, Meltzer H, Ford T, Goodman R. Mental health of children and young people in Great Britain, 2004. 2005. https://doi.org/10.1037/e557702010-001
  2. Conners C, Epstein J, March J, Angold A, Wells K, Klaric J, et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child & Adolescent Psychiatry 2001;40(2):159-167 https://doi.org/10.1097/00004583-200102000-00010
  3. Jensen P, Hinshaw S, Kraemer H, Lenora N, Newcorn J, Abikoff H, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child & Adolescent Psychiatry 2001;40(2):147-158 https://doi.org/10.1097/00004583-200102000-00009
  4. Wilens TE, Spencer TJ, Swanson JM, Connor DF, Cantwell D. Combining methylphenidate and clonidine: a clinically sound medication option. Journal of the American Academy of Child & Adolescent Psychiatry 619;38(5):614-9 https://doi.org/10.1097/00004583-199905000-00025
  5. Swanson JM, Flockhart D, Udrea D, Cantwell D, Connor D, Williams L. Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolesc Psychopharmacol 1995;5(4):301-304. https://doi.org/10.1089/cap.1995.5.301
  6. Popper CW. Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol 1995;5(3):157-166. https://doi.org/10.1089/cap.1995.5.157
  7. Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders. Eur Child Adolesc Psychiatry 2005;14(1):34-40. https://doi.org/10.1007/s00787-005-0424-4
  8. Robertson MM. Attention deficit hyperactivity disorder, tics and Tourette’s syndrome: The relationship and treatment implications. A commentary. Eur Child Adolesc Psychiatry 2006;15(1):1-11. https://doi.org/10.1007/s00787-006-0505-z
  9. Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine Extended-Release Tablets for Pediatric Patients With Attention-Deficit/ Hyperactivity Disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2011 2;50(2):171-179. https://doi.org/10.1016/j.jaac.2010.11.005
  10. Du Y, Li H, Vance A, Zhong Y, Jiao F, Wang H, et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Australasian Psychiatry 2008;42(9):807-813. https://doi.org/10.1080/00048670802277222
  11. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121(1):e73-e84. https://doi.org/10.1542/peds.2006-3695
  12. Sallee FR, Mcgough J, Wigal T, Donahue J, Lyne A, Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. Journal of the American Academy of Child & Adolescent Psychiatry 2009;48(2):155-165. https://doi.org/10.1097/chi.0b013e318191769e
  13. Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care. Medscape Psychiatry Mental Health 2003;8(2).      
  14. Larson K, Russ SA, Kahn RS, Halfon N. Patterns of Comorbidity, Functioning, and Service Use for US Children With ADHD, 2007. Pediatrics 2011;127(3):462-470. https://doi.org/10.1542/peds.2010-0165
  15. Rugino T. A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatric Disease and Treatment 2007;3(3):293-301.         
  16. Sivan M, Neumann V, Kent R, Stroud A, Bhakta BB. Pharmacotherapy for treatment of attention deficits after non- progressive acquired brain injury. A systematic review. Clin Rehabil 2010;24(2):110-121. https://doi.org/10.1177/0269215509343234
  17. Mohammadi MR, Kazemi MR, Rezazadeh SA, Tabrizi M, Akhonzadeh S. amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomised, double-blind trial. Hum Psychopharmacol Clin Exp; 25(7– 8):560-565. https://doi.org/10.1002/hup.1154
  18. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. Journal of attention disorders 2006;9(3):476-485. https://doi.org/10.1177/1087054705284089
  19. Bukstein OG, Arnold LE, Landgraf JM, Hodgkins P. Does switching from oral extended-release methylphenidate to themethylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child and adolescent psychiatry and mental health 2009;3:39. https://doi.org/10.1186/1753-2000-3-39
  20. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997;100(4):662-666. https://doi.org/10.1542/peds.100.4.662
  21. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;110(2):258-266. https://doi.org/10.1542/peds.110.2.258